Company / R&D Expense
Arcturus Therapeutics Holdings Inc. R&D Expense History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$112.2M
FY2025
5-year range
$112.2M / $195.2M
FY2021-FY2025
Trend
-42.5%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $192M to $112M over the past 2 years.
Based on SEC 10-K filings.
$112M in FY2025 with a 5-year CAGR of +45.9%.
Declined from $192M to $112M over the past 2 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -13.6%
- 5-Year CAGR
- +45.9%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +45.9%, indicating consistent growth.
- In FY2025, r&d expense decreased 42.5% year-over-year.
- Peak r&d expense was recorded in FY2024.
- Lowest r&d expense in the period was in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -0.06 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $112.2M | -42.5% |
| FY2024 | $195.2M | +1.6% |
| FY2023 | $192.1M | +10.6% |
| FY2022 | $173.8M | +0.0% |
| FY2021 | $173.8M | +923.2% |
| FY2020 | $17.0M | +0.0% |
| FY2019 | $17.0M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026